[ad_1]
VaxThera, a Colombian biotech company focused on developing vaccines and biologics to contribute to the country’s and the region’s health sovereignty, announced that the United States Patent and Trademark Office (USPTO) has granted a patent for its universal vaccine against coronavirus. It contains a chimeric protein that provides broad protection against different coronaviruses and their different variants.
(READ: Nearly 1.6 million children in Latin America are not fully vaccinated).
“We are proud of the hard work behind this patent. This achievement is a major milestone for VaxThera and demonstrates Columbia’s ability to develop new medicines to address threats and the importance of protecting its intellectual property,” said Dr.
Furthermore, the application has been filed under the Patent Cooperation Treaty (PCT), which allows us to simultaneously seek protection for the invention in other territories such as Colombia, Brazil, India, South Africa and Europe,” said Jorge E. Osorio, President of VaxThera.
The granting of this patent reinforces VaxThera’s positioning and experience as a biotechnology company committed to translating science, research and development into benefits that contribute to improving the quality of life of Colombians and Latin Americans and providing the region with the independent healthcare it needs to face the future of disease.
(You can read: Digital Smart Hospital: A Revolutionary Change in Healthcare).
Notably, Colombia has not produced vaccines since 1998 and, although the Expanded Program on Immunization (PAI) includes 21 vaccines that protect against 26 diseases, none of them are produced locally.
vaccine
Efei
Obtaining this patent is also a recognition of the company’s rigor, innovation, effort and commitment, which, through a painstaking technical process of more than three years, has proven the novelty and industrial applicability of its invention. Daniela Lopera, VaxThera Legal and Regulatory Affairs Director, emphasizes: “Patents are of great strategic importance for companies in the technological sector, especially in the pharmaceutical and biotech sectors, as they are an important means of protecting innovation and stimulating their research and development activities.
In a context of growing global demand for innovative medical solutions, intellectual property rights become a fundamental pillar of progress and competitiveness in the Colombian vaccine industry. Obtaining patents incentivizes investment in research and development, ensuring that companies can use their inventions for the benefit of society. Likewise, it fosters collaboration between institutions, promotes access to advanced technologies and increases the country’s capacity to respond to health challenges.
To achieve this important achievement, VaxThera received support, advice and guidance from Sterne, Kessler, Goldstein & Fox PLLC, a US firm that specializes in IP matters in the biotechnology sector. “The only asset a biotech research startup like VaxThera has at the beginning of its corporate life is its IP. This patent protects the IP in the US market and values the contributions of the company’s pioneering scientists worldwide,” said company founder Dr. Jorge Goldstein, who is considered one of the pioneers of copyright law. USA.
VaxThera, a Colombian company with Seguros SURA as a founding partner, is leveraging its capabilities, collaborative networks, cutting-edge technologies, and national and international experts to help strengthen knowledge transfer and achieve vaccine autonomy in order to be prepared to face future pandemics.
Cesar Giraldo
Associate Editor of Portfolio
[ad_2]
Source link
